WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413091
CAS#: 22494-47-9
Description: Clobuzarit is structurally related to a number of hypolipidemic agents which produce characteristic changes in rodent liver morphology and biochemistry. It is a nonsteroidal anti-inflammatory drug
Hodoodo Cat#: H413091
Name: Clobuzarit
CAS#: 22494-47-9
Chemical Formula: C17H17ClO3
Exact Mass: 304.09
Molecular Weight: 304.770
Elemental Analysis: C, 67.00; H, 5.62; Cl, 11.63; O, 15.75
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Clobuzarit; ICI55,897; ICI-55,897; ICI 55,897
IUPAC/Chemical Name: 2-((4'-Chloro-4-biphenylyl)methoxy)-2-methylpropionic acid
InChi Key: UGOFYAXVVVXMQT-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H17ClO3/c1-17(2,16(19)20)21-11-12-3-5-13(6-4-12)14-7-9-15(18)10-8-14/h3-10H,11H2,1-2H3,(H,19,20)
SMILES Code: CC(C)(OCC1=CC=C(C2=CC=C(Cl)C=C2)C=C1)C(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 304.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Orton TC, Adam HK, Bentley M, Holloway B, Tucker MJ. Clobuzarit: species differences in the morphological and biochemical response of the liver following chronic administration. Toxicol Appl Pharmacol. 1984 Mar 30;73(1):138-51. doi: 10.1016/0041-008x(84)90062-0. PMID: 6424266.
2: Cherkaoui Malki M, Assaka L, Pacot C, Bardot O, Latruffe N. Effect of different hypolipemic agents on rat liver peroxisomal and mitochondrial functions and biogenesis. Cell Mol Biol. 1991;37(7):723-33. PMID: 1777922.
3: Bains SK, Gardiner SM, Mannweiler K, Gillett D, Gibson GG. Immunochemical study on the contribution of hypolipidaemic-induced cytochrome P-452 to the metabolism of lauric acid and arachidonic acid. Biochem Pharmacol. 1985 Sep 15;34(18):3221-9. doi: 10.1016/0006-2952(85)90338-7. PMID: 3929789.
4: Lewis EJ, Bishop J, Cashin CH. Automated quantification of rat plasma acute phase reactants in experimental inflammation. J Pharmacol Methods. 1989 May;21(3):183-94. doi: 10.1016/0160-5402(89)90053-3. PMID: 2471018.
5: Bloxham DP, Bradshaw D, Cashin CH, Dodge BB, Lewis EJ, Westmacott D, Self CR. Biologic properties of romazarit (Ro 31-3948), a potential disease-modifying antirheumatic drug. J Pharmacol Exp Ther. 1990 Mar;252(3):1331-40. PMID: 2156999.
6: Rainsford KD, Davies A, Mundy L, Ginsburg I. Comparative effects of azapropazone on cellular events at inflamed sites. Influence on joint pathology in arthritic rats, leucocyte superoxide and eicosanoid production, platelet aggregation, synthesis of cartilage proteoglycans, synovial production and actions of interleukin-1 in cartilage resorption correlated with drug uptake into cartilage in-vitro. J Pharm Pharmacol. 1989 May;41(5):322-30. doi: 10.1111/j.2042-7158.1989.tb06465.x. PMID: 2569519.
7: el Kebbaj MH, Cherkaoui Malki M, Latruffe N. Effect of peroxisomes proliferators and hypolipemic agents on mitochondrial inner membrane linked D-3-hydroxybutyrate dehydrogenase (BDH). Biochem Mol Biol Int. 1995 Jan;35(1):65-77. PMID: 7735141.
8: Wright V, Dixon JS, Bird HA. Therapeutic significance of laboratory results in rheumatic disease. Semin Arthritis Rheum. 1985 Nov;15(2 Suppl 1):8-13. doi: 10.1016/s0049-0172(85)80003-2. PMID: 2867602.
9: Sheppeard H, Pilsworth LM, Hazleman B, Dingle JT. Effects of antirheumatoid drugs on the production and action of porcine catabolin. Ann Rheum Dis. 1982 Oct;41(5):463-8. doi: 10.1136/ard.41.5.463. PMID: 6812508; PMCID: PMC1001023.
10: McConkey B, Amos RS, Billingham ME, Constable TJ, Crockson RA, Crockson AP, Forster PJ. Rheumatoid arthritis: effects of a new agent (ICI 55 897) on serum acute phase proteins and the erythrocyte sedimentation rate. Ann Rheum Dis. 1980 Feb;39(1):18-21. doi: 10.1136/ard.39.1.18. PMID: 6990881; PMCID: PMC1000463.